In oligometastatic castration-resistant prostate cancer, the rationale to use local SBRT is improved disease control.
Morning Overview on MSN
New prostate cancer immunotherapy slashes biomarkers by up to 99%
An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...
Actinium-225 is a targeted and highly-potent alpha emitter that holds promise for patients who do not respond to lutetium-177 ...
In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...
Reduced-dose ARSI therapy in non-metastatic castration-resistant prostate cancer has similar efficacy and safety as the full dose.
Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results